Conversion to sirolimus in pediatric renal transplant patients: A single-center experience

Pediatric Transplantation

Volumn 16, Issue 6, 2012, Pages 582-588

  Monteverde, Marta L ^a   Ibañez, Juan ^a   Balbarrey, Ziomara ^a   Chaparro, Alicia ^a   Diaz, Mario ^a   Turconi, Amalia ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

adverse events; calcineurin inhibitors; chronic allograft nephropathy; pediatric kidney transplant; sirolimus

Indexed keywords

CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACNE; ANEMIA; APPENDICITIS; ARTHRITIS; ARTICLE; BRAIN TUMOR; CHICKENPOX; CHILD; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERYSIPELAS; FEMALE; FOLLOW UP; GINGIVA HYPERTROPHY; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS DIARRHEA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT; LOWER RESPIRATORY TRACT INFECTION; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEOPLASM; PANCREAS PSEUDOCYST; PERIODONTAL ABSCESS; PNEUMONIA; SCHOOL CHILD; SINUSITIS; STREPTOCOCCAL PHARYNGITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUBERCULOSIS; URINARY TRACT INFECTION;

BIOPSY; CALCINEURIN; CHILD; COHORT STUDIES; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; PEDIATRICS; PROTEINURIA; SIROLIMUS; TREATMENT OUTCOME;

EID: 84864597708     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2012.01697.x     Document Type: Article

References (44)

1. Sharma VK, Bologa RM, Xu GP, et al., Intragraft TGF-beta mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996: 49: 1297-1303. (Pubitemid 26167281)
2. Baboolal K, Jones GA, Janezic A, et al., Molecular and structural consequences of early renal graft injury. Kidney Int 2002: 61: 686-696. (Pubitemid 34102612)
3. Nankivell BJ, Borrows RJ, Fung CL, et al., The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326-2333. (Pubitemid 37509740)
4. Chapman JR, O'Connell PJ, Nankivell BJ,. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005: 16: 3015-3026. (Pubitemid 44743499)
5. The 2010 NAPRCTS Annual Report, Available at:.
6. Gonwa TA, Hricik DE, Brinker K, et al., Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002: 74: 1560-1567. (Pubitemid 36014229)
7. Schenna FP, Pascoe MD, Alberu J, et al., Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009: 87: 233-242.
8. Hymes LC, Warshaw BL,. Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant. Pediatr Transplant 2005: 9: 520-522. (Pubitemid 41153274)
9. Harmon W, Meyers K, Ingelfinger J, et al., Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006: 17: 1735-1745. (Pubitemid 43794677)
10. Weintraub L, Kmbham N, Alexander S, et al., Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. Pediatr Transplant 2008: 12: 541-549.
11. Hymes LC, Warshaw BL, Amaral SG, Greenbaum LA,. Tacrolimus withdrawal and conversion to sirolimus at three months post-pediatric renal transplantation. Pediatr Transplant 2008: 12: 773-777.
12. Hymes LC, Warshaw BL,. Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation. Pediatr Transplant 2011: 15: 437-441.
13. Ibañez J, Monteverde M, Goldberg J, et al., Sirolimus in chronic allograft nephropathy in pediatric recipients. Pediatr Transplant 2007: 11: 777-780. (Pubitemid 47512321)
14. Montanaro D, Gropuzzo M, Tulissi P, et al., Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients. Transplant Proc 2005: 37: 991-993. (Pubitemid 40590769)
15. Schwartz GJ, Munoz A, Schneider MF, et al., New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009: 20: 629-637.
16. N ational H igh B lood P ressure E ducation P rogram W orking G roup on H igh B lood P ressure in C hildren and A dolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004: 114: 555-576.
17. Racussen LC, Solez K, Colvin BR, et al., The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713-719.
18. Solez K, Colvin RB, Racussen LC, et al., Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008: 8: 753-760. (Pubitemid 351347767)
19. Behnke-Hall K, Bauer J, Thul J, et al., Renal function in children with heart transplantation after switching to CNI- free immunosuppression with everolimus. Pediatr Transplant 2011: 15: 784-789.
20. Basso M-S, Subramaian P, Tredger M, et al., Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients. Pediatr Transplant 2011: 15: 722-727.
21. Hoyer P,. Withdrawal of calcineurin inhibitors and switch to mTOR inhibitors-beneficial or too late? Pediatr Transplant 2011: 15: 570-572.
22. Diekmann F, Budde K, Oppenheimer F, et al., Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004: 4: 1869-1875. (Pubitemid 39434449)
23. Diekmann F, Budde K, Slowinski T, et al., Conversion to sirolimus for chronic allograft dysfunction: Long-term results confirm predictive value of proteinuria. Transpl Int 2008: 21: 152-155.
24. Letavernier E, Bruneval P, Vandermeersch S, et al., Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009: 24: 630-638.
25. Biancone L, Bussolati B, Mazzucco G, et al., Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy. Am J Transplant 2010: 10: 2270-2278.
26. Torras J, Herrero Fresneda I, Gulias O, et al., Rapamycin has dual opposing effects on proteinuric experimental nephropathies: Is it a matter of podocyte damage? Nephrol Dial Transplant 2009: 24: 3632-3640.
27. Stallone G, Infante B, Pontelli P, et al., Sirolimus and proteinuria in renal transplant patients: Evidence for a dose-dependent effect on lit diaphragm-associated proteins. Transplantation 2011: 91: 997-2004.
28. Steigerwalt SP, Brar N, Dhunghel A, et al., Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients. Transplant Proc 2009: 41: 4184-4187.
29. Naesens M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009: 4: 481-508.
30. Falger J, Mueller T, Arbeiter K, et al., Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006: 10: 474-479.
31. Van Gelder T, Ter Meulen CG, Hené R, et al., Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003: 75: 788-791. (Pubitemid 36373448)
32. Flechner SM, Feng J, Mastroianni B, et al., The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005: 79: 926-934. (Pubitemid 40586865)
33. Augustine JJ, Bodziak KA, Hricik; DE,. Use of sirolimus in solid organ transplantation. Drugs 2007: 67: 369-391. (Pubitemid 46425551)
34. Grinyo JM, Cruzado JM,. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006: 6: 1991-1999. (Pubitemid 44199533)
35. Al-Uzri A, Yorgin PD, Kling PJ,. Anemia in children after transplantation: Etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant 2003: 7: 253-264. (Pubitemid 36988279)
36. Morrone LF, Di Paolo S, Logoluso F, et al., Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: Role of growth factors and cytokines. Transplantation 1997: 64: 913-918. (Pubitemid 27422277)
37. Gossmann J, Thurmann P, Bachmann T, et al., Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996: 50: 973-978. (Pubitemid 26302687)
38. Alvarez Gacia O, Carbajo Perez E, Garcia E, et al., Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 2007: 22: 954-959.
39. Alvarez García O, García Lopez E, Loredo V, et al., Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. Kidney Int 2010: 78: 561-568.
40. Fristsche L, Budde K, Dragun D, et al., Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004: 4: 130-131. (Pubitemid 38155499)
41. Zuber J, Anglicheau D, Elie C, Berehi L, et al., Sirolimus may reduce fertility in male transplant recipients. Am J Transplant 2008: 7: 1471-1479. (Pubitemid 351989493)
42. Gonzalez D, Garcia CD, Azucar M,. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol, 2011: 26: 961-966.
43. Hymes LC, Warshaw BL,. Linear growth in pediatric renal transplant recipients receiving sirolimus. Pediatr Transplant 2011: 15: 570-572.
44. Fine RN,. Growth post renal-transplantation in children: Lessons from the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1997: 1: 85-89. (Pubitemid 127684812)